Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Jun 5;30(6):295–300. doi: 10.1002/clc.20101

Effects of Insulin Dependence on Inflammatory Process, Thrombotic Mechanisms and Endothelial Function, in Patients with Type 2 Diabetes Mellitus and Coronary Atherosclerosis

Charalambos Antoniades 1,✉, Dimitris Tousoulis 1, Kyriakoula Marinou 1, Nikos Papageorgiou 1, Erini Bosinakou 1, Costas Tsioufis 1, Elli Stefanadi 1, George Latsios 1, Costas Tentolouris 1, Gerasimos Siasos 1, Christodoulos Stefanadis 1
PMCID: PMC6653670  PMID: 17551966

Abstract

Background

Type 2 diabetes mellitus (T2DM) is characterized by endothelial dysfunction, increased thrombogeneisity and abnormal inflammatory response.

Hypothesis

We hypothesizsed that insulin dependence/exogenous insulin administration may affect thrombotic/inflammatory status and endothelial function in patients with T2DM and coronary artery disease (CAD).

Methods

Fifty‐five patients with T2DM + CAD (26 insulin‐treated (INS) and 29 under oral biguanide + sulphonylurea (TABL)) were recruited. Endothelial function was assessed by gauge‐strain plethysmography, and serum levels of inflammatory and thrombotic markers were determined by enzyme linked immunosorbent assay.

Results

There was no significant difference in endothelium‐dependent dilation (EDD) between the study groups, while EDD was correlated with fasting glucose levels in both INS (r = − 0.776, p = 0.0001) and TABL (r = − 0.702, p = 0.0001). Patients in INS group had higher levels of interleukin‐6 (IL‐6), tumor necrosis factor alpha (TNF‐α), monocyte chemoattractant protein (MCP‐1) and vascular cell adhesion molecule (sVCAM‐1), compared to TABL. However, TNF‐α was negatively correlated with protein C (PrtC) only in INS (r = − 0.726, p = 0.01) but not in TABL group (r = − 0.066, p = 0.738). Similarly, sVCAM‐1 was correlated with PrtC only among INS patients (r = − 0.451, p = 0.046) but not in TABL (r = 0.069, p = 0.727). In multivariate analysis, insulin dependence was a predictor of IL‐6, TNF‐α, MCP‐1 and sVCAM‐1 levels independently from the patients' demographic characteristics, the angiographic extend of CAD or the duration of diabetes.

Conclusions

Insulin treatment in patients with type 2 diabetes mellitus affects the expression of inflammatory cytokines and subsequently modifies the thrombotic mechanisms in patients with coronary atherosclerosis, independently from the duration of diabetes and the extend of coronary artery disease. Copyright © 2007 Wiley Periodicals, Inc.

Keywords: endothelium, inflammation, coronary artery disease, diabetes mellitus

Full Text

The Full Text of this article is available as a PDF (308.3 KB).

References

  • 1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without Prior Myocardial Infarction. N Engl J Med 1998; 339: 229–234. [DOI] [PubMed] [Google Scholar]
  • 2. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, et al.: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925–1931. [DOI] [PubMed] [Google Scholar]
  • 3. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111–1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, et al.: Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996; 120: 7–14. [DOI] [PubMed] [Google Scholar]
  • 5. Sjoholm A, Nystrom T: Endothelial inflammation in insulin resistance. Lancet 2005; 365: 610–612. [DOI] [PubMed] [Google Scholar]
  • 6. Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27(suppl 3): S53–S55. [DOI] [PubMed] [Google Scholar]
  • 7. Muis MJ, Bots ML, Grobbee DE, Stolk RP: Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet Med 2005; 22: 118–126. [DOI] [PubMed] [Google Scholar]
  • 8. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511–2515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Laakso M, Edelman SV, Brechtel G, Baron AD: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990; 85: 1844–1852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. National Diabetes Data Group : Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039–1057. [DOI] [PubMed] [Google Scholar]
  • 11. Tousoulis D, Antoniades C, Stefanadis C: Evaluating endothelial function in humans: a guide to invasive and non‐invasive techniques. Heart 2005; 91: 553–558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Pyorala M, Miettinen H, Laakso M, Pyorala K: Plasma insulin and all‐cause, cardiovascular, and noncardiovascular mortality: the 22‐year follow‐up results of the Helsinki Policemen Study. Diabetes Care 2000; 23: 1097–1102. [DOI] [PubMed] [Google Scholar]
  • 13. Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708–723. [DOI] [PubMed] [Google Scholar]
  • 14. Dandona P, Aljada A, Mohanty P: The anti‐inflammatory and potential anti‐atherogenic effect of insulin: a new paradigm. Diabetologia 2002; 45: 924–930. [DOI] [PubMed] [Google Scholar]
  • 15. Aljada A, Ghanim H, Saadeh R, Dandona P: Insulin inhibits NFkappaB and MCP‐1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001; 86: 450–453. [DOI] [PubMed] [Google Scholar]
  • 16. Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P: Insulin inhibits the expression of intercellular adhesion molecule‐1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab 2000; 85: 2572–2575. [DOI] [PubMed] [Google Scholar]
  • 17. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, et al.: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti‐inflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257–3265. [DOI] [PubMed] [Google Scholar]
  • 18. Harte A, McTernan P, Chetty R, Coppack S, Katz J, et al.: Insulin‐mediated Upregulation of the renin angiotensin system in Human Subcutaneous Adipocytes is reduced by Rosiglitazone. Circulation 2005; 111: 1954–1961. [DOI] [PubMed] [Google Scholar]
  • 19. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B: Hyperinsulinemia enhances transcriptional activity of nuclear factor‐kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000; 87: 746–752. [DOI] [PubMed] [Google Scholar]
  • 20. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, et al.: Randomized trial of insulin‐glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57–65. [DOI] [PubMed] [Google Scholar]
  • 21. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, et al.: Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998; 98: 2227–2234. [DOI] [PubMed] [Google Scholar]
  • 22. Calles‐Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 36–52. [DOI] [PubMed] [Google Scholar]
  • 23. Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, et al.: Insulin potentiates platelet‐derived growth factor action in vascular smooth muscle cells. Endocrinology 1998; 139: 4067–4072. [DOI] [PubMed] [Google Scholar]
  • 24. Vischer UM, Emeis JJ, Bilo HJ, Stehouwer CD, Thomsen C, et al.: von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII). Thromb Haemost 1998; 80: 1002–1007. [PubMed] [Google Scholar]
  • 25. Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat 2001; 15: 44–54. [DOI] [PubMed] [Google Scholar]
  • 26. Yamamoto K, Shimokawa T, Kojima T, Loskutoff DJ, Saito H: Regulation of murine protein C gene expression in vivo: effects of tumor necrosis factor‐alpha, interleukin‐1, and transforming growth factor‐beta. Thromb Haemost 1999; 82: 1297–1301. [PubMed] [Google Scholar]
  • 27. Vukovich TC, Schernthaner G: Decreased protein C levels in patients with insulin‐dependent type I diabetes mellitus. Diabetes 1986; 35: 617–619. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES